ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 168, Issue 4, 2015, Pages 274-283

  Breitenstein, Barbara ^a,b,c   Brückl, Tanja Maria ^b   Ising, Marcus ^b   Müller Myhsok, Bertram ^b,d,e   Holsboer, Florian ^a,b   Czamara, Darina ^b  

^a HMNC GmbH   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF TRIER   (Germany)

^d Munich Cluster for Systems Neurology ^*  (Germany)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

ABCB1; Antidepressant treatment; Major depression; MDR1; P glycoprotein

Indexed keywords

ANTIDEPRESSANT AGENT; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ABCB1 GENE; ARTICLE; BLOOD BRAIN BARRIER; DEPRESSION ASSESSMENT; DRUG UPTAKE; ETHNICITY; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE VARIANT; GENETIC ASSOCIATION; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MEDICATION COMPLIANCE; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PHENOTYPE; PRIORITY JOURNAL; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SELF REPORT; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; DEPRESSIVE DISORDER, MAJOR; GENETICS; HAPLOTYPE; SAMPLE SIZE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SAMPLE SIZE;

EID: 84929509874     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32309     Document Type: Article

References (47)

1. Breitenstein B, Scheuer S, Pfister H, Uhr M, Lucae S, Holsboer F, Ising M, Brückl TM. 2013. The clinical application of ABCB1 genotyping in antidepressant treatment: A pilot study. CNS Spectr Jul 23: S. 1-11. [Epub ahead of print].
2. Bundgaard C, Jensen CJN, Garmer M. 2012. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice. Drug Metab Dispos 40:461-466.
3. De Klerk OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, den Boer JA, Bruggeman R, Hoogendijk WJ, Penninx BW. 2013. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J 13(4):349-353.
4. Dong C, Wong M-L, Licinio J. 2009. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: Association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 14:1105-1118.
5. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CECA, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C. 2005. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174.
6. Ejsing TB, Hasselstrøm J, Linnet K. 2006. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabol Drug Interact 21:139-162.
7. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. 2008. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36:268-275.
8. GENDEP Investigators, MARS Investigators, and SI. 2013. Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 170:207-217.
9. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry J-M, Bondolfi G, Bertschy G. 2008. CYP2D6 and ABCB1 Genetic variability: Influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 30:474-482.
10. Grauer MT, Uhr M. 2004. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J Psychopharmacol 18:66-74.
11. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB. 2011. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 21:152-161.
12. Holsboer F. 2008. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 9:638-646.
13. Huang X, Yu T, Li X, Cao Y, Li X, Liu B, Yang F, Li W, Zhao X, Feng G, Zhang X, Dong Z, He L, Sun X, He G. 2013. ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics 14:1723-1730.
14. Karlsson L, Carlsson B, Hiemke C, Ahlner J, Bengtsson F, Schmitt U, Kugelberg FC. 2013. Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment. Eur Neuropsychopharmacol 23:1636-1644.
15. Karlsson L, Hiemke C, Carlsson B, Josefsson M, Ahlner J, Bengtsson F, Schmitt U, Kugelberg FC. 2011. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology (Berl) 215:367-377.
16. Karlsson L, Schmitt U, Josefsson M, Carlsson B, Ahlner J, Bengtsson F, Kugelberg FC, Hiemke C. 2010. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 20:632-640.
17. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T. 2008. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32:398-404.
18. Khan A, Leventhal RM, Khan SR, Brown WA. 2002. Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22:40-45.
19. Kocsis JH, Croughan JL, Katz MM, Butler TP, Secunda S, Bowden CL, Davis JM. 1990. Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 147:621-624.
20. Kongkaew C, Sakunrag I, Jianmongkol P. 2012. Non-compliance with digoxin in patients with heart failure and/or atrial fibrillation: A systematic review and meta-analysis of observational studies. Arch Cardiovasc Dis 105:507-516.
21. Laika B, Leucht S, Steimer W. 2006. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): Lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem 52:893-895.
22. Lin K-M, Chiu Y-F, Tsai I-J, Chen C-H, Shen WW, Liu SC, Lu S-C, Liu C-Y, Hsiao M-C, Tang H-S, Liu S-I, Chang L-H, Wu C-S, Tsou H-H, Tsai M-H, Chen C-Y, Wang S-M, Kuo H-W, Hsu Y-T, Liu Y-L. 2011. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 21:163-170.
23. Menu P, Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E. 2010. Antidepressants and ABCB1 gene C3435T functional polymorphism: A naturalistic study. Neuropsychobiology 62:193-197.
24. Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M. 2008. MDR1 gene polymorphism: Therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32:1439-1444.
25. Moncrieff J. 2003. A comparison of antidepressant trials using active and inert placebos. Int J Methods Psychiatr Res 12:117-127.
26. Niitsu T, Fabbri C, Bentini F, Serretti A. 2013. Pharmacogenetics in major depression: A comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 45:183-194.
27. Nikisch G, Eap CB, Baumann P. 2008. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. Pharmacol Res 58:344-347.
28. O'Brien FE, Clarke G, Dinan TG, Cryan JF, Griffin BT. 2013. Human P-glycoprotein differentially affects antidepressant drug transport: Relevance to blood-brain barrier permeability. Int J Neuropsychopharmacol 16:2259-2272.
29. O'Brien FE, Dinan TG, Griffin BT, Cryan JF. 2012. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: Clinical significance of in vitro and in vivo findings. Br J Pharmacol 165:289-312.
30. Ottevanger EA. 1994. The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiatry 18:731-740.
31. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. 2010. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 67:1110-1113.
32. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP. 2008. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE 3:e1872.
33. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. 2002. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2:191-196.
34. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 163:1905-1917.
35. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM. 2010. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 20:467-475.
36. Serretti A, Kato M, Kennedy JL. 2008. Pharmacogenetic studies in depression: A proposal for methodologic guidelines. Pharmacogenomics J 8:90-100.
37. Singh AB, Bousman CA, Ng CH, Byron K, Berk M. 2012. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry 2:e198.
38. Stouffer SA, Suchman EA, Devinney LC, Star SA, Williams RM Jr. 1949. The American Soldier, Vol.1: Adjustment during Army Life. Princeton University Press, Princeton.
39. Uher R, Perroud N, Ng MYM, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P. 2010. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 167:555-564.
40. Uhr M, Grauer MT. 2003. Abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 37:179-185.
41. Uhr M, Grauer MT, Holsboer F. 2003. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54:840-846.
42. Uhr M, Grauer MT, Yassouridis A, Ebinger M. 2007. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res 41:179-188.
43. Uhr M, Steckler T, Yassouridis A, Holsboer F. 2000. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22:380-387.
44. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Pütz B, Binder EB, Müller-Myhsok B, Holsboer F. 2008. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57:203-209.
45. Wang J-S, Zhu H-J, Gibson BB, Markowitz JS, Donovan JL, DeVane CL. 2008. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull 31:231-234.
46. Warden D, Trivedi MH, Carmody T, Toups M, Zisook S, Lesser I, Myers A, Kurian KRB, Morris D, John Rush A. 2014. Adherence to Antidepressant Combinations and Monotherapy for Major Depressive Disorder: A CO-MED Report of Measurement-Based Care. J Psychiatr Pract 20:118-132.
47. WHO. 2012. Depression: A Global Public Health Concern.